Zhejiang East-Asia Pharmaceutical (605177.SH): The raw material drug Lu Likang received the South Korean raw material drug registration certificate.

15:34 20/01/2025

East Asia Pharmaceutical (605177.SH) issued an announcement that they recently received approval from the South Korean Food and Drug Administration (Korea...

Zhejiang East-Asia Pharmaceutical (605177.SH) announced that recently, the company has received the raw material drug registration certificate from the South Korean Ministry of Food and Drug Safety (Korean MFDS) for the product named Voriconazole. Voriconazole is used to treat skin superficial fungal infections caused by sensitive fungi, such as athlete's foot, body ringworm, jock itch, and can also be used for cutaneous candidiasis and tinea versicolor. The receipt of the Voriconazole raw material drug registration certificate in South Korea marks the company's eligibility for market access in South Korea. This will have a positive impact on expanding the company's presence in the South Korean pharmaceutical market, thus promoting the sales of Voriconazole raw material drugs in other overseas markets.

On October 28th, BILLION IND (02299) spent 168,300 Hong Kong dollars to repurchase 38,000 shares.

FIRST TRACTOR (00038): Huang Yating appointed as joint company secretary and authorized representative.

WH GROUP (00288): Henan Shuanghui Investment & Development's net profit attributable to shareholders for the first three quarters was 3.959 billion yuan, an increase of 4.1% year-on-year.

On October 28th, BILLION IND (02299) spent 168,300 Hong Kong dollars to repurchase 38,000 shares.

FIRST TRACTOR (00038): Huang Yating appointed as joint company secretary and authorized representative.

WH GROUP (00288): Henan Shuanghui Investment & Development's net profit attributable to shareholders for the first three quarters was 3.959 billion yuan, an increase of 4.1% year-on-year.